| 1425 |
National Cancer Institute |
Html |
en |
Ewing Sarcoma Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of Ewing sarcoma. |
| ewing sarcoma | 0.955451 |
| Localized Ewing Sarcoma | 0.516622 |
| standard-risk Ewing sarcoma | 0.50921 |
| localized ewing tumors | 0.458678 |
| pelvic ewing sarcoma | 0.53548 |
| non-metastatic ewing | 0.447666 |
| Ewing family tumors | 0.476484 |
| Cooperative Ewing Sarcoma | 0.57252 |
| Primary Ewing tumor | 0.442949 |
| genetically confirmed Ewing | 0.443739 |
| recurrent Ewing sarcoma | 0.50281 |
| high-risk Ewing sarcoma | 0.510965 |
| soft tissue ewing | 0.474262 |
| Ewing sarcoma regimen | 0.517079 |
| Sarcoma Studies patients | 0.436849 |
| sarcoma treatment | 0.437736 |
| ewing sarcoma family | 0.677203 |
| Ewing sarcoma patients | 0.582131 |
| Ewing tumor patients | 0.46609 |
| Ewing Sarcoma Study | 0.512708 |
| radiation therapy | 0.475396 |
| Cutaneous Ewing sarcoma | 0.543452 |
| Ewing sarcoma trials | 0.520061 |
| extraosseous Ewing sarcoma. | 0.438839 |
| et al. | 0.575718 |
|
| extraskeletal Ewing sarcoma | 0.55299 |
| tissue Ewing sarcoma | 0.517715 |
| sarcoma family tumors | 0.500986 |
| Ewing sarcoma molecularly. | 0.525686 |
| nonmetastatic Ewing sarcoma | 0.582468 |
| secondary Ewing sarcoma | 0.532715 |
| PUBMED Abstract | 0.436153 |
| extraosseus Ewing tumors | 0.450361 |
| extraosseous ewing sarcoma | 0.608612 |
| Pediatr Blood Cancer | 0.643087 |
| prognosis Ewing family | 0.435199 |
| Intergroup Cooperative Ewing | 0.452427 |
| advanced Ewing tumors | 0.44875 |
| nonmetastatic extraosseous Ewing | 0.439621 |
| subcutaneous Ewing sarcoma | 0.543232 |
| Ewing sarcoma. | 0.468942 |
| primary Ewing sarcoma | 0.527784 |
| Abstract | 0.588175 |
| Clin Oncol | 0.669349 |
| multifocal Ewing sarcoma | 0.559473 |
| metastatic Ewing tumors | 0.450872 |
| Ewing tumor | 0.52176 |
| ewing tumors | 0.573464 |
| non metastatic Ewing | 0.435213 |
|
CLICK HERE |
| 1534 |
National Cancer Institute |
Html |
en |
Cartilage (Bovine and Shark) (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the use of bovine and shark cartilage as a treatment for people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only. |
| angiogenesis inhibitor | 0.605921 |
| cartilage factor | 0.525431 |
| cartilage research | 0.52625 |
| cartilage powder | 0.542054 |
| cartilage treatment | 0.554222 |
| shark cartilage | 0.973124 |
| shark cartilage extracts | 0.55218 |
| Biol Response Mod | 0.51035 |
| cartilage cells | 0.557954 |
| new blood vessels | 0.487052 |
| tumor angiogenesis | 0.46716 |
| dry shark cartilage | 0.564932 |
| bovine cartilage | 0.627952 |
| patients | 0.494925 |
| Natl Cancer Inst | 0.505572 |
| vascular endothelial growth | 0.488146 |
| novel shark cartilage | 0.566963 |
| bovine cartilage extract | 0.544409 |
| bovine cartilage extracts | 0.534781 |
| shark cartilage extract | 0.575893 |
| powdered shark cartilage | 0.660454 |
| metastatic renal cell | 0.492793 |
| Japanese shark cartilage | 0.557325 |
| new endothelial cells | 0.468808 |
|
| shark cartilage products | 0.552328 |
| endothelial cells | 0.499823 |
| cartilage products | 0.616806 |
| Oral shark cartilage | 0.568829 |
| angiogenesis inhibitors | 0.486536 |
| PUBMED Abstract | 0.506075 |
| epiphyseal cartilage | 0.523025 |
| cartilage tissue | 0.520334 |
| endothelial cell proliferation | 0.510942 |
| bovine cartilage preparations | 0.556431 |
| human cartilage | 0.516475 |
| shark cartilage-derived angiogenesis | 0.484691 |
| Catrix treatment | 0.468204 |
| shark cartilage product | 0.595815 |
| cartilage therapy | 0.532177 |
| Abstract | 0.525209 |
| endothelial cell | 0.516176 |
| renal cell carcinoma | 0.554811 |
| phase i/ii trial | 0.471371 |
| cartilage-derived collagenase inhibitor | 0.469151 |
| tumor | 0.475092 |
| shark cartilage inhibitor | 0.566866 |
| cancer | 0.518101 |
| bovine cartilage therapies | 0.544621 |
|
CLICK HERE |
| 1727 |
National Cancer Institute |
Html |
en |
Bone Cancer |
A fact sheet about the diagnosis and treatment of cancers that develop in the bones. |
| benign bone tumors | 0.382978 |
| soft tissue | 0.317275 |
| osteoid tissue | 0.26524 |
| uncommon cancer | 0.255981 |
| primary bone cancer | 0.577561 |
| cancer cells | 0.329155 |
| abnormal bone tissue | 0.376855 |
| metastatic cancer | 0.262213 |
| bone scan | 0.325169 |
| anticancer drugs | 0.274172 |
| Cancer Information Service | 0.273277 |
| Yes. Cancer | 0.261575 |
| tumor causes production | 0.259064 |
| healthy bone tissue | 0.408981 |
| Yes. Bone cancer | 0.36265 |
| Cancer Treatment Research | 0.2781 |
| preoperative tumor treatment | 0.265675 |
| healthy tissue | 0.254742 |
| fibrous tissue | 0.263622 |
| clinical trials | 0.344137 |
| bone tissue | 0.452141 |
| primitive nerve tissue | 0.285777 |
| heredity cancer syndromes | 0.279206 |
| normal bone tissue | 0.410848 |
|
| Clinical Trials page | 0.251984 |
| Ewing Sarcoma Family | 0.249697 |
| soft tissue sarcomas | 0.285733 |
| incisional biopsy | 0.250026 |
| tissue sample | 0.258655 |
| blood vessels | 0.251489 |
| high-dose external radiation | 0.249703 |
| spongy tissue | 0.268691 |
| bone marrow | 0.344367 |
| cancer centers | 0.251332 |
| different types | 0.282598 |
| doctor | 0.249686 |
| new bone cells | 0.361397 |
| bones | 0.259461 |
| important treatment option | 0.251744 |
| radiation therapy | 0.277888 |
| treatment options | 0.263715 |
| bone cancer | 0.911469 |
| comprehensive cancer information | 0.27281 |
| research studies | 0.263781 |
| cancerous bone cells | 0.36956 |
| bone cancers | 0.35903 |
| African American children | 0.253491 |
|
CLICK HERE |
| 1731 |
National Cancer Institute |
Html |
en |
Oral Contraceptives and Cancer Risk |
A fact sheet about research on the association of oral contraceptive use (birth control pills) with risk of various cancers. |
| oral contraceptives | 0.917263 |
| hereditary ovarian cancer | 0.383854 |
| commonly prescribed type | 0.33973 |
| liver cancer risk | 0.373941 |
| estrogen-progestogen contraceptives | 0.386723 |
| benign liver tumors | 0.371652 |
| risk level | 0.342841 |
| increased risk | 0.351993 |
| time oral contraceptives | 0.52153 |
| ovarian cancer | 0.597198 |
| cervical cancers | 0.357191 |
| birth control pills | 0.477503 |
| cervical cancer | 0.513015 |
| female hormones | 0.362642 |
| hormonal factors | 0.355222 |
| widely used contraceptives | 0.420798 |
| slightly higher risk | 0.352236 |
| oral contraceptive formulations | 0.41375 |
| human papillomavirus | 0.360793 |
| endometrial cancer | 0.391533 |
| Cancer Epidemiology Biomarkers | 0.379203 |
| Cancer Clinical Study | 0.356619 |
| women | 0.413442 |
| study | 0.369792 |
| United States | 0.339309 |
|
| low progestin levels | 0.339553 |
| endometrial cancer risk | 0.376136 |
| oral contraceptive contains | 0.427683 |
| oral contraception | 0.377158 |
| breast cancers | 0.339078 |
| National Cancer Institute | 0.35154 |
| oral contraceptive. | 0.39193 |
| epithelial ovarian cancer | 0.36885 |
| female hormones estrogen | 0.346135 |
| ovarian cancer risk | 0.5032 |
| epidemiological studies | 0.347746 |
| cervical cancer risk | 0.402371 |
| higher risk | 0.352753 |
| hormonal contraceptives | 0.40794 |
| breast cancer risk | 0.408785 |
| protective effect increases | 0.369195 |
| Abstract | 0.338219 |
| breast cancer | 0.500449 |
| malignant liver tumors | 0.371449 |
| birth control pill | 0.342382 |
| cancer risk | 0.531533 |
| et al | 0.421561 |
| New England Journal | 0.388183 |
| cancer | 0.613253 |
|
CLICK HERE |
| 1868 |
National Cancer Institute |
Html |
es |
Tratamiento del linfoma de Hodgkin infantil (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del linfoma de Hodgkin infantil. |
| lymphocyte predominant hodgkin | 0.379318 |
| Cancer Statistics Review | 0.310924 |
| patients with hodgkin | 0.340461 |
| Epstein-Barr virus with | 0.308343 |
| lymphocyte predominance hodgkin | 0.361894 |
| Pediatric Lymphocyte-Predominant Hodgkin | 0.335497 |
| with nodular lymphocyte | 0.31309 |
| Epstein-Barr virus | 0.324897 |
| localized childhood hodgkin | 0.334572 |
| familial classical hodgkin | 0.33579 |
| células reed-sternberg | 0.313182 |
| Radiat Oncol Biol | 0.310379 |
| oncology group study | 0.317944 |
| adolescent hodgkin | 0.33572 |
| Children's Oncology Group | 0.329911 |
| Estados Unidos | 0.310464 |
| siguientes caracterÃsticas | 0.32336 |
| Leuk Lymphoma | 0.318529 |
| hodgkin's lymphoma | 0.723879 |
| childhood hodgkin | 0.361352 |
| SEER Cancer Statistics | 0.312001 |
| classic hodgkin | 0.335243 |
| pediatric hodgkin | 0.427701 |
| IV Hodgkin | 0.334995 |
| adultos jóvenes | 0.32544 |
|
| estadio iv | 0.319107 |
| nodular lymphocyte-predominant hodgkin | 0.387944 |
| nodular sclerosing hodgkin | 0.337374 |
| high-risk hodgkin | 0.334348 |
| pediatric patients with | 0.317448 |
| with hodgkin | 0.425646 |
| linfadenopatÃa periférica | 0.308361 |
| non-Hodgkin's lymphoma | 0.3114 |
| advanced hodgkin | 0.335086 |
| National Cancer Institute | 0.316464 |
| report from | 0.308961 |
| with classical hodgkin | 0.37144 |
| Hodgkin's lymphoma after | 0.346052 |
| Epstein-Barr virus infection | 0.309022 |
| células reed-sternberg llamadas | 0.308458 |
| Pediatr Hematol Oncol | 0.310971 |
| Lymphoma project | 0.310216 |
| Clin Oncol | 0.390721 |
| Hodgkin Lymphoma Group | 0.341816 |
| Oncol Biol Phys | 0.310469 |
| hodgkin lymphoma | 0.986519 |
| lymphocyte-predominant hodgkin lymphoma | 0.45063 |
| Cancer Institute | 0.316934 |
| classical hodgkin lymphoma | 0.529436 |
|
CLICK HERE |
| 1889 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de colon (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de colon. |
| siguientes procedimientos | 0.92972 |
| pequeña cantidad | 0.497446 |
| estadio ii | 0.856655 |
| tubo recolector | 0.46569 |
| rayos x | 0.562684 |
| inferior.ampliar procedimiento | 0.480242 |
| enlace drugs approved | 0.587222 |
| escáner tep | 0.457465 |
| proteÃna llamada factor | 0.458005 |
| National Cancer Institute | 0.432943 |
| sustancia llamada gadolinio | 0.497309 |
| siguientes riesgos | 0.425516 |
| Instituto Nacional | 0.460477 |
| PDQ Tratamiento | 0.671072 |
| estadio iiia | 0.656788 |
| antecedentes familiares | 0.459139 |
|
| estadio iiic | 0.63832 |
| cáncer.ampliar sigmoidoscopia | 0.46788 |
| estadio iiib | 0.647408 |
| estadio iia | 0.819513 |
| estadio iic | 0.81663 |
| células cancerosas.El bevacizumab | 0.49983 |
| Physician Data Query | 0.524312 |
| Rectal Cancer | 0.499997 |
| cuerpo).ampliar anatomÃa | 0.468805 |
| crecer.El ziv-aflibercept | 0.437476 |
| antÃgeno carcinoembrionario | 0.577035 |
| PDQ Cánceres | 0.540215 |
| colon forma | 0.990115 |
| tejidos sanos circundantes | 0.470011 |
| Estadio IVA | 0.522216 |
| siguientes pruebas | 0.469066 |
|
CLICK HERE |
| 1995 |
National Cancer Institute |
Html |
es |
Tratamiento de la histiocitosis de células de Langerhans (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos sobre el tratamiento de la histiocitosis de células de Langerhans infantil. |
| Immunol Cell Biol | 0.40642 |
| langerhans cell | 0.852012 |
| lesiones hcl | 0.406571 |
| with langerhans | 0.417161 |
| langerhans cell histiocytosis | 0.986891 |
| multisystem langerhans | 0.422209 |
| BRAF V600E-negative Langerhans | 0.406114 |
| Langerhans-cell histiocytosis | 0.403191 |
| cutaneous langerhans | 0.405301 |
| células dendrÃticas mieloides | 0.413633 |
| BRAF Mutation Correlates | 0.403764 |
| braf mutation | 0.404571 |
| pulmonary langerhans | 0.409447 |
| pediatric-onset multisystem langerhans | 0.405705 |
| HCL multisistémica | 0.436981 |
| pulmonary langerhans cell | 0.407403 |
| Grois N | 0.403041 |
| cell histiocytosis patients | 0.407759 |
| Cell Histiocytosis Study | 0.404713 |
| cell histiocytosis harboring | 0.404154 |
| mutación v600e | 0.406931 |
| dendritic cell differentiation | 0.403188 |
| mutación braf v600e | 0.411753 |
| histiocytosis lesions reveals | 0.403971 |
| Arch Dis Child | 0.403576 |
|
| Emile JF | 0.403241 |
| epidermal langerhans cells | 0.412171 |
| HCL dérmica | 0.409229 |
| BRAF V600E | 0.436151 |
| Pediatr Blood Cancer | 0.419983 |
| lesiones óseas | 0.406722 |
| With High-Risk Langerhans | 0.411149 |
| mutaciones braf v600e | 0.404471 |
| Multiresistant Langerhans Cell | 0.407509 |
| mutación braf | 0.412372 |
| braf inhibitor | 0.402661 |
| Med Pediatr Oncol | 0.402927 |
| Clin Oncol | 0.402664 |
| with braf | 0.403023 |
| células circulantes | 0.409275 |
| adult pulmonary langerhans | 0.405666 |
| HCL CD1a-positivas | 0.409797 |
| Langerhans'-cell histiocytosis | 0.405031 |
| High-Risk Langerhans Cell | 0.421727 |
| oncogén braf | 0.403238 |
| tratamiento inicial.la hcl | 0.405836 |
| with epidermal langerhans | 0.411581 |
| childhood langerhans | 0.408867 |
| French Langerhans | 0.405677 |
|
CLICK HERE |
| 2010 |
National Cancer Institute |
Html |
es |
Grados de comprobación científica de los estudios de investigación sobre detección y prevención del cáncer (PDQ®)–Versión para profesionales de salud |
Información acerca de cómo evaluar la solidez de los datos probatorios obtenidos en los estudios de investigación sobre detección y prevención del cáncer. |
| Woolf SH | 0.300601 |
| Helfand M | 0.300564 |
| sección datos | 0.302661 |
| Current methods | 0.300631 |
| importancia clÃnica | 0.300524 |
| Consejo editorial usa | 0.301821 |
| datos probatorios indirectos | 0.302664 |
| Prev Med | 0.300645 |
| beneficios opción | 0.300848 |
| National Cancer Institute | 0.300824 |
| medida estudios | 0.300552 |
| Preventive Services Task | 0.303591 |
| Instituto Nacional | 0.30261 |
|
| Visuals Online | 0.300487 |
| intervenciones invasoras | 0.300666 |
| Harris RP | 0.300578 |
| Physician Data Query | 0.300891 |
| Services Task Force | 0.303562 |
| datos probatoriosUn estudio | 0.301838 |
| posibles beneficios | 0.30077 |
| datos probatorios | 0.994126 |
| acuerdo vs | 0.301691 |
| participantes vs | 0.301672 |
| US Preventive Services | 0.301 |
| perjuicios opción | 0.301319 |
| mejores estudios | 0.300602 |
|
CLICK HERE |
| 2956 |
National Cancer Institute |
Html |
en |
Stress and Smoking |
Many people smoke when they feel stressed. A major part of quitting smoking is finding ways to handle your stress. Get tips on ways you can reduce stress in your life. |
| mood | 0.321745 |
| yoga | 0.311766 |
| smokers | 0.257588 |
| effective—like | 0.254092 |
| body | 0.252396 |
| short walk | 0.459288 |
| lowers | 0.345038 |
| ways | 0.478317 |
| problem | 0.256426 |
| solution | 0.253633 |
| smoking | 0.723433 |
| things | 0.251219 |
| nicotine feel | 0.464166 |
| healthy ways | 0.416006 |
| oxygen | 0.318701 |
| quitting | 0.25513 |
|
| unpleasant feelings | 0.498181 |
| stress | 0.995674 |
| relaxation exercise | 0.463458 |
| cigarette | 0.258889 |
| emotions | 0.253066 |
| withdrawal | 0.2602 |
| Nicotine addiction | 0.459283 |
| brain | 0.303202 |
| people | 0.263655 |
| long-term stress reliever | 0.883552 |
| calms nerves | 0.742794 |
| cigarettes | 0.42465 |
| depression | 0.30341 |
| time | 0.25441 |
| better ways | 0.410713 |
| Cravings | 0.267404 |
|
CLICK HERE |
| 3932 |
National Cancer Institute |
Html |
es |
Aprenda a relajarse |
Ejercicios de relajación y de visualización para ayudar a reducir el dolor y el estrés del cáncer y de su tratamiento. |
| pequeña almohada | 0.868399 |
|
| agradable sensación | 0.763417 |
|
CLICK HERE |